BackContineum Therapeutics Overview

Contineum Therapeutics Operating Income

Track Contineum Therapeutics's operating income ($-72M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly Operating Income

$-20966000.00
↑ 40.41% YoY

As of Sep 30, 2026

Annual Operating Income (TTM)

$-72413000.00
↑ 6.51% YoY

Trailing 12 months ending Sep 30, 2026

Average Operating Income (Comparison Companies)

Operating Income History

Operating Income Comparison

Annual Operating Income Growth Rate (%)

Annual Operating Income Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin

Contineum Therapeutics (CTNM) FAQ

As of the most recent data (September 2026), CTNM shows a operating income of $-72M. That compares with $-68M in the prior-year period — down 6.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CTNM's operating income is now $-72M (was $-68M) — a 6.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Contineum Therapeutics is outperforming or lagging.

Tracking CTNM's operating income over time shows whether Contineum Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $-72M That compares with $-68M in the prior-year period — down 6.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Contineum Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-72M) with ownership activity and broader fundamentals.